PriceTargets.com logo

Sesen Bio - SESN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 03/7/2023 01:00 AM ET
+0 (0.00%)
Get New Sesen Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SESN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SESN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Sesen Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for SESN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sesen Bio. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
8/10/2021HC WainwrightReiterated RatingBuy$160.00Low
2/17/2021HC WainwrightBoost TargetBuy$45.00 ➝ $160.00Low
11/13/2019HC WainwrightReiterated RatingBuy$45.00Low
8/9/2019LaidlawDowngradeBuy ➝ HoldHigh
6/11/2019HC WainwrightUpgradeNeutral ➝ Buy$20.00 ➝ $60.00Medium
5/14/2019HC WainwrightReiterated RatingHold$20.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sesen Bio logo
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $10.50
Low: $0.63
High: $12.99

52 Week Range

Now: N/A

Volume

93,330 shs

Average Volume

1,067,298 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Sesen Bio?

The following Wall Street analysts have issued research reports on Sesen Bio in the last twelve months: StockNews.com.
View the latest analyst ratings for SESN.

What is the current price target for Sesen Bio?

0 Wall Street analysts have set twelve-month price targets for Sesen Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sesen Bio in the next year.
View the latest price targets for SESN.

What is the current consensus analyst rating for Sesen Bio?

Sesen Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SESN.

What other companies compete with Sesen Bio?

Other companies that are similar to Sesen Bio include Janux Therapeutics, Evotec, Summit Therapeutics, Indivior and Corcept Therapeutics. Learn More about companies similar to Sesen Bio.

How do I contact Sesen Bio's investor relations team?

Sesen Bio's physical mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company's listed phone number is (617) 444-8550 and its investor relations email address is [email protected]. The official website for Sesen Bio is www.sesenbio.com. Learn More about contacing Sesen Bio investor relations.